nach oben

Reviews in Endocrine and Metabolic Disorders

Erschienen in:

21.11.2016

Flushing in (neuro)endocrinology

verfasst von: Fady Hannah-Shmouni, Constantine A. Stratakis, Christian A. Koch

Erschienen in: Reviews in Endocrine and Metabolic Disorders | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Cutaneous flushing is a common presenting complaint in endocrine disorders. The pathophysiology of flushing involves changes in cutaneous blood flow triggered by multiple intrinsic factors that are either related to physiology or disease. Flushing can be divided into episodic or persistent causes. Episodic flushing is mediated by the release of endogenous vasoactive mediators or medications, while persistent flushing results in a fixed facial erythema with telangiectasia and cyanosis due to slow-flowing deoxygenated blood in large cutaneous blood vessels. The differential diagnosis of cutaneous flushing in neuroendocrine disorders is limited, yet encompasses a broad spectrum of benign and malignant entities, including carcinoid syndrome, pheochromocytoma, Cushing syndrome, medullary thyroid cancer, and pancreatic neuroendocrine tumors. In this review, we provide a concise and up-to-date discussion on the differential diagnosis and approach of flushing in neuroendocrinology.

Ikizoglu G. Red face revisited: flushing. Clin Dermatol. 2014;32:800–8.CrossRefPubMed

Ray D, Williams G. Pathophysiological causes and clinical significance of flushing. Br J Hosp Med. 1993;50:594–8.PubMed

Aldrich LB, Moattari AR, Vinik AI. Distinguishing features of idiopathic flushing and carcinoid syndrome. Arch Intern Med. 1988;148:2614–8.CrossRefPubMed

Stratakis CA, Mastorakos G, Mitsiades NS, Mitsiades CS, Chrousos GP. Skin manifestations of Cushing disease in children and adolescents before and after the resolution of hypercortisolemia. Pediatr Dermatol. 1998;15(4):253–8.

Metcalfe DD. Differential diagnosis of the patient with unexplained flushing/anaphylaxis. Allergy Asthma Proc. 2000;21:21–4.CrossRefPubMed

Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC, Alvarez-Twose I, et al. Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis, the American Academy of Allergy, Asthma & Immunology, and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol. 2016;137(1):35–45.CrossRefPubMed

De Filippis EA, Sabet A, Sun MR, Garber JR. Pemberton’s sign: explained nearly 70 years later. J Clin Endocrinol Metab. 2014;99(6):1949–54.CrossRefPubMed

Jukic T, Kusic Z. Pemberton’s sign in patient with substernal goiter. J Clin Endocrinol Metab. 2010;95(9):4175.CrossRefPubMed

Schnirer II, Yao JC, Ajani JA. Carcinoid—a comprehensive review. Acta Oncol. 2003;42:672–92.CrossRefPubMed

10.

Feldman JM. Carcinoid tumors and the carcinoid syndrome. Curr Probl Surg. 1989;26(12):835–85.CrossRefPubMed

11.

Singh S, Asa SL, Dey C, Kennecke H, Laidley D, Law C, et al. Diagnosis and management of gastrointestinal neuroendocrine tumors: an evidence-based Canadian consensus. Cancer Treat Rev. 2016;47:32–45.CrossRefPubMed

12.

Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, Goldsmith SJ, et al.; North American Neuroendocrine Tumor Society (NANETS). The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas. 2010;39(6):753–66.

13.

Liu EH, Solorzano CC, Katznelson L, Vinik AI, Wong R, Randolph G. AACE/ACE disease state clinical review: diagnosis and management of midgut carcinoids. Endocr Pract. 2015;21:534–45.CrossRefPubMedPubMedCentral

14.

O’Toole D, Kianmanesh R, Caplin M. ENETS 2016 consensus guidelines for the management of patients with digestive neuroendocrine tumors: an update. Neuroendocrinology. 2016;103(2):117–8.CrossRefPubMed

15.

Kulke MH, Shah MH, Benson 3rd AB, Bergsland E, Berlin JD, Blaszkowsky LS, et al. Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw. 2015;13(1):78–108.PubMed

16.

Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendto K, Chan JA, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42(4):557–77.CrossRefPubMedPubMedCentral

17.

Crocetti E, Paci E. Malignant carcinoids in the USA, SEER 1992–1999. An epidemiological study with 6830 cases. Eur J Cancer Prev. 2003;12:191–4.CrossRefPubMed

18.

Ganim RB, Norton JA. Recent advances in carcinoid pathogenesis, diagnosis and management. Surgical Oncol. 2000;9:173–9.CrossRef

19.

Koch CA, Azumi N, Furlong MA, Jha RC, Kehoe TE, Trowbridge CH, et al. Carcinoid syndrome caused by an atypical carcinoid of the uterine cervix. J Clin Endocrinol Metab. 1999;84(11):4209–13.CrossRefPubMed

20.

Vinik AI, Gonin J, England BG, Jackson T, McLeod MK, Cho K. Plasma substance-P in neuroendocrine tumors and idiopathic flushing: the value of pentagastrin stimulation tests and the effects of somatostatin analog. J Clin Endocrinol Metab. 1990;70(6):1702–9.CrossRefPubMed

21.

Balks HJ, Conlon JM, Creutzfeldt W, Stockmann F. Circulating bradykinin-like immunoreactivity and the pentagastrin-induced carcinoid flush. Clin Endocrinol. 1988;29(2):141–51.CrossRef

22.

Parson HK, Harati H, Cooper D, Vinik AI. Role of prostaglandin D2 and the autonomous nervous system in niacin-induced flushing. J Diabetes. 2013;5(1):59–67.CrossRefPubMed

23.

Belch JJ, Small M, McKenzie F, Hill PA, Lowe GD, McIntyre DE, et al. DDAVP stimulates prostacyclin production. Thromb Haemost. 1982;47(2):122–3.PubMed

24.

Feldman JM, O’Dorisio TM. Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am J Med. 1986;81:41–8.CrossRefPubMed

25.

Eriksson B, Oberg K, Stridsberg M. Tumor markers in neuroendocrine tumors. Digestion. 2000;62 Suppl 1:33–8.CrossRefPubMed

26.

Nehar D, Lombard-Bohas C, Olivieri S, et al. Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol. 2004;60:644–52.CrossRef

27.

Ruszniewski P, Ish-Shalom S, Wymenga M, O’Toole D, Arnold R, Tomassetti P, et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology. 2004;80:244–51.CrossRefPubMed

28.

Pokuri VK, Fong MK, Iyer R. Octreotide and lanreotide in gastroenteropancreatic neuroendocrine tumors. Curr Oncol Rep. 2016;18(1):7.CrossRefPubMed

29.

Woltering EA, Wright AE, Stevens MA, Wang YZ, Boudreaux JP, Mamikunian G, et al. Development of effective prophylaxis against intraoperative carcinoid crisis. J Clin Anesth. 2016;32:189–93.CrossRefPubMed

30.

Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:1915–42.CrossRefPubMed

31.

Chen H, Sippel RS, O’Dorisio MS, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010;39:775–83.CrossRefPubMedPubMedCentral

32.

Kopetschke R, Slisko M, Kilisli A, Tuschy U, Wallaschofski H, Fassnacht M, et al. Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. Eur J Endocrinol. 2009;161(2):355–61.CrossRefPubMed

33.

Plouin PF, Degoulet P, Tugaye A, Ducrocq MB, Menard J. Screening for phaeochromocytoma: in which hypertensive patients ? A semiological study of 2585 patients, including 11 with phaeochromocytoma. Nouv Presse Med. 1981;10(11):869–72.PubMed

34.

Metz SA, Halter JB, Porte Jr D, Robertson RP. Suppression of plasma catecholamines and flushing by clonidine in man. J Clin Endocrinol Metab. 1978;46:83–90.CrossRefPubMed

35.

McGuinness ME, Talbert RL. Pharmacologic stress testing: experience with dipyridamole, adenosine, and dobutamine. Am J Hosp Pharm. 1994;51:328–46. quiz 404–5.PubMed

36.

Mouri T, Takahashi K, Sone M, et al. Calcitonin gene-related peptide-like immunoreactivities in pheochromocytomas. Peptides. 1989;10:201–4.CrossRefPubMed

37.

Herrera MF, Stone E, Deitel M, Asa SL. Pheochromocytoma producing multiple vasoactive peptides. Arch Surg. 1992;127:105–8.CrossRefPubMed

38.

Smith SL, Slappy AL, Fox TP, Scolapio JS. Pheochromocytoma producing vasoactive intestinal peptide. Mayo Clin Proc. 2002;77:97–100.CrossRefPubMed

39.

Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Matsuo H, Eto T. Isolation and characterization of peptides which act on rat platelets, from a pheochromocytoma. Biochem Biophys Res Commun. 1992;185:134–41.CrossRefPubMed

40.

Letizia C, Rossi G, Cerci S. Adrenomedullin and endocrine disorders. Panminerva Med. 2003;45:241–51.PubMed

41.

Nicholls MG, Lainchbury JG, Lewis LK, et al. Bioactivity of adrenomedullin and proadrenomedullin N-terminal 20 peptide in man. Peptides. 2001;22:1745–52.CrossRefPubMed

42.

Gläsker S, Neumann HPH, Koch CA, Vortmeyer AO. Von Hippel-Lindau Disease. In: De Groot LJ, Beck-Peccoz P, Chrousos G, Dungan K, Grossman A, Hershman JM, Koch C, McLachlan R, New M, Rebar R, Singer F, Vinik A, Weickert MO, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. 2015 Jul 11.

43.

Wells Jr SA, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25:567–610.CrossRefPubMedPubMedCentral

44.

Koch CA. Molecular pathogenesis of MEN2-associated tumors. Fam Cancer. 2005;4(1):3–7.CrossRefPubMed

45.

Brauer VF, Scholz GH, Neumann S, Lohmann T, Paschke R, Koch CA. RET germline mutation in codon 791 in a family representing 3 generations from age 5 to age 70 years: should thyroidectomy be performed? Endocr Pract. 2004;10(1):5–9.CrossRefPubMed

46.

Lepage C, Bouvier AM, Phelip JM, Hatem C, Vernet C, Faivre J. Incidence and management of malignant digestive endocrine tumours in a well defined French population. Gut. 2004;53:549–53.CrossRefPubMedPubMedCentral

47.

Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19:1727–33.CrossRefPubMedPubMedCentral

48.

Kimura W, Kuroda A, Morioka Y. Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases. Dig Dis Sci. 1991;36:933–42.CrossRefPubMed

49.

Miehle K, Tannapfel A, Lamesch P, Borte G, Schenker E, Kluge R, et al. Pancreatic neuroendocrine tumor with ectopic adrenocorticotropin production upon second recurrence. J Clin Endocrinol Metab. 2004;89(8):3731–6.CrossRefPubMed

50.

Nilubol N, Freedman EM, Quezado MM, Patel D, Kebebew E. Pancreatic neuroendocrine tumor secreting vasoactive intestinal peptide and dopamine with pulmonary emboli: a case report. J Clin Endocrinol Metab. 2016;101(10):3564–7.CrossRefPubMed

51.

Baur AD, Pavel M, Prasad V, Denecke T. Diagnostic imaging of pancreatic neuroendocrine neoplasms (pNEN): tumor detection, staging, prognosis, and response to treatment. Acta Radiol. 2016;57(3):260–70.CrossRefPubMed

52.

Stratakis CA. Diagnosis and clinical genetics of Cushing syndrome in pediatrics. Endocrinol Clin N Am. 2016;45:311–28.CrossRef

53.

Robyn JA, Koch CA, Montalto J, Yong A, Warne GL, Batch JA. Cushing’s syndrome in childhood and adolescence. J Paediatr Child Health. 1997;33(6):522–7.CrossRefPubMed

54.

Lindholm J, Juul S, Jorgensen JO, et al. Incidence and late prognosis of Cushing’s syndrome: a population-based study. J Clin Endocrinol Metab. 2001;86:117–23.PubMed

55.

Etxabe J, Vazquez JA. Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol. 1994;40:479–84.CrossRef

56.

Afshari A, Ardeshirpour Y, Lodish MB, et al. Facial plethora: modern technology for quantifying an ancient clinical sign and its use in Cushing syndrome. J Clin Endocrinol Metab. 2015;100:3928–33.CrossRefPubMedPubMedCentral

57.

McReynolds SM, Freidberg SR, Guay AT, Lee AK, Pazianos AG, Hussain SF. Hot flushes in men with pituitary adenoma. Surg Neurol. 1995;44:14–7. discussion 7–8.CrossRefPubMed

58.

Myers BM, Miralles GD, Taylor CA, Gastineau DA, Pisani RJ, Talley NJ. POEMS syndrome with idiopathic flushing mimicking carcinoid syndrome. Am J Med. 1991;90:646–8.CrossRefPubMed

59.

Niepomniszcze H, Amad RH. Skin disorders and thyroid diseases. J Endocrinol Invest. 2001;24:628–38.CrossRefPubMed

60.

Zouboulis CC, Liakou AI. Images in clinical medicine. Flashing, pulsating angioma. N Engl J Med. 2012;366(24):e36.CrossRefPubMed

61.

Seo I, Bargo PR, Kollias N. Simultaneous assessment of pulsating and total blood in inflammatory skin lesions using functional diffuse reflectance spectroscopy in the visible range. J Biomed Opt. 2010;15(6):060507.CrossRefPubMed

62.

Sassarini J, Lumsden MA. Vascular function and cardiovascular risk factors in women with severe flushing. Maturitas. 2015;80:379–83.CrossRefPubMed

63.

Crandall CJ, Manson JE, Hohensee CM, Horvath S, Wactawski-Wende J, LeBlanc, E, et al. Association of genetic variation in the tachykinin receptor 3 locus with hot flashes and night sweats in the Women’s Health Initiative Study. Menopause. Published ahead of print.

64.

Krause MS, Nakaijma ST. Hormonal and nonhormonal treatment of vasomotor symptoms. Obstet Gyncecol Clin N Am. 2015;42:163–79.CrossRef

65.

Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, et al. Treatment of symptoms of the menopause: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975–4011.CrossRefPubMed

Titel: Flushing in (neuro)endocrinology
verfasst von: Fady Hannah-Shmouni
Constantine A. Stratakis
Christian A. Koch
Publikationsdatum: 21.11.2016
Verlag: Springer US
Erschienen in: Reviews in Endocrine and Metabolic Disorders / Ausgabe 3/2016
Print ISSN: 1389-9155
Elektronische ISSN: 1573-2606
DOI: https://doi.org/10.1007/s11154-016-9394-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Flushing in (neuro)endocrinology

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2016

Beyond acne: Current aspects of sebaceous gland biology and function

Skin steroidogenesis in health and disease

Targeting the vitamin D endocrine system (VDES) for the management of inflammatory and malignant skin diseases: An historical view and outlook

Nutrition and skin

Neuroendocrinology of the skin

Endocrine manifestations of systemic mastocytosis in bone

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin